Portal:AOP/FeaturedPathways
From WikiPathways
 COVID-19 AOP (Homo sapiens) |
 Mitochondrial Complex I inhibition leading to parkinsonian motor deficits (Homo sapiens) |
 Mitochondrial Complex I inhibition leading to chemical induced fanconi syndrome (Homo sapiens) |
 Mitochondrial Complex inhibition leading to liver injury (Homo sapiens) |
 Protein alkylation leading to liver fibrosis (Homo sapiens) |
 Lung fibrosis (Homo sapiens) |
 Lung fibrosis (Mus musculus) |
Image does not exist Epilepsy Adverse Outcome Pathway (Homo sapiens) |
|
Image does not exist Liver steatosis AOP (Homo sapiens) |
Image does not exist Steatosis AOP (Homo sapiens) |
Image does not exist Selective serotonin reuptake inhibitors lead to several adverse outcomes (Homo sapiens) |
Image does not exist Gastric ulcer formation (Homo sapiens) |
 Nanoparticle-mediated activation of receptor signaling (Homo sapiens) |
 Nanomaterial induced apoptosis (Homo sapiens) |
 Nanoparticle triggered regulated necrosis (Homo sapiens) |
 Nanoparticle triggered autophagic cell death (Homo sapiens) |
 Overview of nanoparticle effects (Homo sapiens) |
 Nanomaterial induced inflammasome activation (Homo sapiens) |
 Nanoparticle-mediated activation of receptor signaling (Bos taurus) |
 ACE2 inhibition leads to lung fibrosis (Homo sapiens) |
|
List of featured pathways: |
